Does sertraline cause gynaecomastia? This is a question raised by some patients and clinicians, given that sertraline — a widely prescribed SSRI in the UK — can theoretically influence prolactin levels via serotonergic pathways. Whilst gynaecomastia is not listed as a recognised adverse reaction in the current sertraline Summary of Product Characteristics (SmPC), a small number of case reports have described breast tissue changes in patients taking SSRIs. This article explores the proposed mechanisms, how common this association is, when to seek medical advice, and how the MHRA's Yellow Card scheme supports ongoing safety monitoring.

Can Sertraline Cause Gynaecomastia?

Sertraline is not confirmed to cause gynaecomastia; it is absent from the current SmPC adverse reaction list, though rare case reports propose an indirect mechanism via serotonin-stimulated prolactin elevation.

Sertraline is a selective serotonin reuptake inhibitor (SSRI) widely prescribed in the UK for depression, anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder. It works by blocking the reuptake of serotonin in the brain, increasing its availability in the synaptic cleft and thereby improving mood regulation. Whilst sertraline is generally well tolerated, questions are sometimes raised about whether it can contribute to gynaecomastia — the benign enlargement of glandular breast tissue in males.

There is no definitive, well-established causal link between sertraline and gynaecomastia. Reviewing the current sertraline Summary of Product Characteristics (SmPC), as held on the MHRA's medicines information database (accessible via the electronic Medicines Compendium, emc), gynaecomastia is not listed as a recognised adverse reaction; galactorrhoea (abnormal nipple discharge) is the breast-related adverse effect more commonly noted in SSRI product information. Patients and clinicians should consult the most up-to-date SmPC for the specific sertraline product prescribed, as wording may vary between licensed products.

Nevertheless, a small number of case reports in the medical literature have described gynaecomastia occurring in patients taking SSRIs, including sertraline. The proposed mechanism is theoretical and indirect: elevated serotonin activity may modestly stimulate prolactin secretion from the anterior pituitary gland — a condition known as hyperprolactinaemia — which in turn can promote breast tissue development. It is important to note that hyperprolactinaemia with SSRIs is uncommon, and galactorrhoea has been reported in some cases even with normal prolactin levels, suggesting additional mechanisms may be involved. The overall evidence for this pathway remains limited and is based primarily on case reports rather than controlled studies.

Gynaecomastia is a multifactorial condition. Other contributing factors include hormonal imbalances (such as altered oestrogen-to-testosterone ratios), other medications (including spironolactone, finasteride, anti-androgens, and cimetidine, which carry stronger evidence of association than many other drug classes), liver disease, obesity, and natural hormonal changes during puberty or ageing. Therefore, if gynaecomastia develops during sertraline treatment, it should not automatically be attributed to the medication without a thorough clinical assessment. Patients are encouraged to discuss any new breast changes with their GP rather than stopping sertraline abruptly, as sudden discontinuation can cause discontinuation syndrome.

How Common Is Gynaecomastia With Antidepressants?

Gynaecomastia associated with antidepressants, including sertraline, is considered rare and is based on isolated case reports; antipsychotics carry a more clearly established risk due to direct dopamine D2 receptor antagonism.

Gynaecomastia associated with antidepressant use is considered rare in the published literature, though the true incidence is difficult to quantify precisely. Most of the available evidence comes from isolated case reports and pharmacovigilance databases rather than large-scale randomised controlled trials, which means robust prevalence figures are not currently available. Among SSRIs as a class, the association with gynaecomastia is not well characterised, and sertraline specifically has only been implicated in a limited number of documented cases. It should be noted that robust comparative incidence data between individual SSRIs are lacking, and it would not be accurate to suggest meaningful differences in risk between agents within the class on current evidence.

By contrast, certain other psychotropic medications carry a more clearly established risk. Antipsychotics — particularly first-generation agents such as haloperidol and second-generation drugs such as risperidone — are more strongly associated with hyperprolactinaemia and subsequent gynaecomastia due to their dopamine D2 receptor antagonism, which directly disinhibits prolactin release. Tricyclic antidepressants have also been linked to gynaecomastia in some reports, though again the evidence base is limited.

For SSRIs including sertraline, any indirect serotonergic effect on prolactin is generally considered modest compared with antipsychotics. Most patients taking sertraline will never experience any breast-related changes. However, individual susceptibility varies, and factors such as age, body composition, concurrent medications, and underlying health conditions may influence whether a person is more likely to notice breast tissue changes. Clinicians should maintain a broad differential diagnosis when evaluating gynaecomastia in any patient taking sertraline, carefully reviewing the full medication list and relevant medical history before attributing the symptom to the antidepressant alone.

When to Speak to a GP or Pharmacist

New breast enlargement, tenderness, or nipple discharge during sertraline treatment should prompt prompt GP review; investigations may include prolactin, sex hormones, liver function, and thyroid function tests, with urgent two-week-wait referral if cancer features are present.

Anyone who notices new or progressive breast tissue enlargement, breast tenderness, or nipple discharge whilst taking sertraline should seek advice from their GP or a community pharmacist promptly. A pharmacist can provide initial advice and signpost to appropriate care, but any decision to alter or stop medication should be made with the prescribing clinician. Whilst gynaecomastia is most often benign, it is important to rule out other underlying causes, some of which may require specific investigation or treatment.

A GP will typically take a detailed medication and clinical history, perform a physical examination (including testicular examination where clinically indicated), and may arrange investigations in line with NICE CKS guidance on gynaecomastia. These may include:

• Prolactin levels — to assess for hyperprolactinaemia

• Testosterone, oestradiol, LH, and FSH — to evaluate sex hormone balance and gonadal function

• Sex hormone-binding globulin (SHBG) — to assess free androgen availability

• Liver function tests — as liver disease can impair oestrogen metabolism

• Thyroid function tests — since thyroid disorders can contribute to gynaecomastia

• Renal function (U&Es) — as renal disease may be a contributing factor

• Beta-hCG and alpha-fetoprotein — if a testicular germ cell tumour is suspected, with scrotal ultrasound considered where appropriate

Patients should not stop taking sertraline without medical guidance. Abrupt discontinuation can lead to discontinuation syndrome, characterised by symptoms such as dizziness, nausea, flu-like feelings, and mood disturbance.

In line with NICE guidance on suspected cancer (NG12), GPs should consider an urgent two-week-wait referral for men aged 30 years or over with an unexplained breast lump, or for those aged 50 years or over with unexplained nipple changes (such as discharge, retraction, or skin changes). Features such as a hard or irregular lump, skin tethering, or nipple retraction should prompt urgent assessment to exclude male breast cancer, which — although rare — must not be missed. Referral to an endocrinologist may be appropriate where a hormonal cause is identified or suspected.

Managing Gynaecomastia Whilst Continuing Treatment

Management should be collaborative, weighing mental health benefits against breast changes; options include watchful waiting, switching antidepressant, or — for confirmed persistent gynaecomastia — specialist-supervised off-label medical treatment or surgical referral.

For many patients, the mental health benefits of continuing sertraline will outweigh the risk or inconvenience of mild breast tissue changes, particularly if gynaecomastia is not confirmed as drug-related. Management decisions should always be made collaboratively between the patient and their prescriber, taking into account the severity of the breast changes, the patient's mental health stability, and the availability of alternative treatments.

If sertraline is considered a likely contributing factor and the gynaecomastia is causing significant distress, a GP may consider switching to a different antidepressant. Mirtazapine, which acts via a different mechanism and has a lower theoretical association with prolactin elevation, may be a clinically reasonable option in some cases; however, the choice of alternative should be guided by the individual clinical picture rather than assumptions about class-wide differences in risk, as robust comparative evidence is lacking. Any switch should be managed carefully with an appropriate cross-tapering schedule to minimise discontinuation effects and maintain therapeutic efficacy.

In cases where gynaecomastia is confirmed and persistent, further management options — guided by NICE CKS recommendations — may include:

• Watchful waiting — mild gynaecomastia often resolves spontaneously, particularly if the causative factor is identified and addressed. Early intervention (generally within approximately 12 months of onset) is more likely to be effective, as longstanding gynaecomastia may involve fibrotic tissue that responds less well to medical or pharmacological treatment

• Medical treatment — short-term use of tamoxifen (an oestrogen receptor antagonist) or aromatase inhibitors has been used in some cases. It is important to note that these treatments are off-label for gynaecomastia in the UK and should only be initiated and supervised by a specialist (typically an endocrinologist or breast surgeon)

• Surgical referral — for longstanding or significant gynaecomastia causing psychological distress, surgical correction (subcutaneous mastectomy or liposuction-assisted techniques) may be considered via NHS referral

Patients should be reassured that gynaecomastia, whilst potentially distressing, is not dangerous in itself. Maintaining open communication with the prescribing clinician is essential to ensure both mental health and physical wellbeing are appropriately managed.

MHRA Guidance and Reporting Side Effects in the UK

The MHRA's Yellow Card scheme allows patients and clinicians to report suspected adverse reactions to sertraline, including gynaecomastia, helping to identify emerging safety signals and keep prescribing guidance up to date.

Experiencing these side effects? Our pharmacists can help you navigate them →

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK body responsible for regulating medicines and monitoring their safety once they are in use. Post-marketing surveillance — the ongoing monitoring of medicines after they have been licensed — plays a crucial role in identifying rare or previously unrecognised side effects, including those that may not have been apparent during clinical trials.

In the UK, both healthcare professionals and patients can report suspected adverse drug reactions (ADRs) through the Yellow Card scheme, which is operated by the MHRA. If a patient or clinician suspects that sertraline or any other medicine has caused gynaecomastia or another unexpected side effect, submitting a Yellow Card report is encouraged. Reports can be made online at the MHRA Yellow Card website (yellowcard.mhra.gov.uk), via the Yellow Card app, or through a GP or pharmacist. These reports contribute to the national pharmacovigilance database and help the MHRA identify emerging safety signals that may prompt label updates or regulatory action.

The current sertraline SmPC, accessible via the electronic Medicines Compendium (emc) at medicines.org.uk, does not list gynaecomastia as a recognised adverse reaction, reinforcing that any association remains unconfirmed at a regulatory level. Galactorrhoea is the breast-related adverse effect more commonly referenced in SSRI product information. Patients and clinicians are encouraged to consult the SmPC for the specific sertraline product in use, as product information is subject to periodic revision.

Following the UK's departure from the European Union, the MHRA now operates its pharmacovigilance functions independently, though it continues to collaborate with international regulatory partners including the European Medicines Agency (EMA).

Patients taking sertraline should be encouraged to read the patient information leaflet supplied with their medication and to report any unexpected symptoms to their GP, pharmacist, or directly to the MHRA via the Yellow Card scheme. Proactive reporting helps protect public health and ensures that prescribing guidance remains up to date and evidence-based.

Frequently Asked Questions